Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCWB220
- Development stage
- Preclinical
- Lead developer
- GC Wellbeing
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
GCWB220 is a high-dose intravenous formulation of acetaminophen (paracetamol) being developed by GC Green Cross Wellbeing. It is designed for the short-term treatment of moderate pain, particularly post-operative pain. Acetaminophen acts primarily in the central nervous system to alleviate pain and reduce fever, likely through the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are involved in prostaglandin synthesis. GCWB220 has completed stability studies and is positioned as a new injectable pain management option.
- Other names
- high-dose acetaminophen injection고용량 아세트아미노펜주
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on GCWB220.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCWB220.